Saturday 17 October 2026
Export CRIS’s income statement to Excel — free account
Curis, Inc.
CRIS Healthcare Biotechnology
Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024. In the quarter to June 2026, revenue fell 66.0%, EPS grew 70.4% and free cash flow fell 20.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.41
0.10
−19.61%
Follow CRIS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 1.38 | 2.23 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (2.05) | (4.67) | |
P/B ratio |
— | — | 2.39 | 0.00 | |
Price to Tangible BV |
— | — | 0.00 | 0.00 | |
EV/Sales |
— | — | 0.97 | 1.56 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (0.34) | (0.60) | |
EV/FCF |
— | — | (0.33) | (0.60) | |
Quick Ratio |
0.41 | 1.00 | 0.36 | 0.62 | |
Current Ratio |
0.49 | 1.11 | 0.49 | 0.70 | |
Net Debt/EBITDA |
0.57 | 1.30 | (0.26) | 1.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.31 | 0.33 | |
Operating CF/Net income |
1.12 | 0.37 | (0.33) | 0.72 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | 22.65 | (7.82) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 511.86% | 202.52% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 253.34% | 115.02% | |
Intangible Assets out of Total Assets |
0.47 | 0.30 | 0.45 | 0.33 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 69.86% | 29.09% | |
Graham Net Nets |
— | — | (0.58) | (1.09) | |
Graham Number |
— | — | 0.00 | 175.92 | |
Earnings Yield |
— | — | (120.20%) | (221.08%) | |
Free Cash Flow Yield |
— | — | (211.91%) | (117.20%) | |
Revenue per Share |
0.00 | 0.00 | 1.73 | 4.05 | |
Operating CF per Share |
(4.52) | (9.30) | (9.68) | (7.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.52) | (9.30) | (9.68) | (7.10) | |
Cash per Share |
2.63 | 15.49 | 7.69 | 11.54 | |
Shareholders Equity per Share |
2.20 | 13.12 | 8.30 | (18.74) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.20 | 13.12 | 8.30 | (18.74) | |
Free Cash Flow |
(9.65) | (9.00) | (6.37) | (5.57) | |
Working Capital |
(6.95) | 1.64 | (7.16) | (6.00) | |
Net Current Asset Value |
(7.55) | (0.37) | (7.59) | (28.42) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 3.11 | |
Average Payables |
4.74 | 5.92 | 4.32 | 4.13 | |
Average Assets |
24.10 | 34.51 | 30.62 | 35.06 | |
Average Common Equity |
(4.65) | 3.05 | (0.27) | (11.71) |
Columns are period end dates